The finding that G-CIMP+ glioblastomas harbor lowered levels of EGFR signaling is largely consistent with the previous observation that IDH mutated, G-CIMP+ glioblastomas exhibited lowered likelihood of PTEN loss of heterozygosity or EGFR amplification [4]. The gene discussed is IDH2; the disease is glioblastoma.